title: A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
abstract: ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥ 3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
authors.affiliation: Department of Infection and Population Health, University College London, Rowland Hill St, London, NW3 2PF, UK, a.mocroft@ucl.ac.uk.
authors.forename: A
authors.initials: A
authors.lastname: Mocroft
authors.forename: P
authors.initials: P
authors.lastname: Reiss
authors.forename: A
authors.initials: A
authors.lastname: Rakhmanova
authors.forename: D
authors.initials: D
authors.lastname: Banhegyi
authors.forename: A N
authors.initials: AN
authors.lastname: Phillips
authors.forename: S
authors.initials: S
authors.lastname: De Wit
authors.forename: M
authors.initials: M
authors.lastname: Ristola
authors.forename: J D
authors.initials: JD
authors.lastname: Lundgren
authors.forename: J
authors.initials: J
authors.lastname: Grarup
authors.forename: O
authors.initials: O
authors.lastname: Kirk
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003625:Data Collection; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D004363:Drug Utilization; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D005060:Europe; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D010078:Oxazines / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D019380:Anti-HIV Agents; D004338:Drug Combinations; D000068257:Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D063065:Organophosphonates; D010078:Oxazines; D003841:Deoxycytidine; D000225:Adenine